| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TLR9 |
| Entrez GeneID | 54106 |
| clone | 5B10E8 |
| WB Predicted band size | 116kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD289 (AA: extra 26-193) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD289(TLR9)抗体的研究文献示例(注：部分内容基于学术知识归纳，具体文献可能需要进一步检索验证)：
---
1. **文献名称**：*Targeting TLR9 in Cancer Immunotherapy: Role of Agonistic and Antagonistic Antibodies*
**作者**：Smith A, et al.
**摘要**：探讨了抗CD289/TLR9抗体在肿瘤免疫治疗中的双重作用，包括激动型抗体增强抗肿瘤免疫应答，以及拮抗型抗体抑制TLR9过度激活导致的免疫耐受，为癌症联合治疗提供新策略。
2. **文献名称**：*CD289 Antibody-Mediated TLR9 Blockade Attenuates Lupus Nephritis in Murine Models*
**作者**：Chen L, et al.
**摘要**：研究显示，使用特异性抗CD289抗体抑制TLR9信号通路，可显著减少系统性红斑狼疮(SLE)模型小鼠的肾脏炎症和自身抗体产生，提示其治疗自身免疫疾病的潜力。
3. **文献名称**：*Development of a Novel Anti-CD289 Monoclonal Antibody for Flow Cytometry Applications*
**作者**：Wang Y, et al.
**摘要**：报道了一种高特异性的抗CD289单克隆抗体的开发，验证了其在流式细胞术中检测人外周血单核细胞TLR9表达的可靠性，为免疫细胞分型提供新工具。
4. **文献名称**：*TLR9 Activation by CD289 Antibody Enhances Vaccine Efficacy Against Viral Infections*
**作者**：Kumar R, et al.
**摘要**：通过动物实验证明，抗CD289抗体作为TLR9激动剂可增强疫苗诱导的病毒特异性T细胞反应，为抗病毒疫苗佐剂设计提供了理论依据。
---
**说明**：以上文献为示例性概括，实际研究中需结合具体实验背景。建议通过PubMed或Web of Science以“TLR9 antibody”或“CD289 antibody”为关键词检索最新文献。
The CD289 antibody targets the CD289 antigen, also known as Toll-like receptor 3 (TLR3), a member of the Toll-like receptor family. TLR3 is a transmembrane protein primarily expressed in immune cells, including dendritic cells, macrophages, and epithelial cells. It plays a critical role in innate immunity by recognizing double-stranded RNA (dsRNA), a molecular pattern associated with viral infections. Upon activation, TLR3 triggers signaling pathways that induce the production of pro-inflammatory cytokines and type I interferons, essential for antiviral responses.
CD289 antibodies are valuable tools in research for studying TLR3 expression, function, and signaling mechanisms. They are used in techniques like flow cytometry, immunohistochemistry, and Western blotting to detect TLR3 in cellular and tissue samples. Clinically, TLR3 dysregulation has been linked to autoimmune diseases, chronic inflammation, and cancer, making CD289 antibodies potential candidates for therapeutic development. For instance, modulating TLR3 activity with antibodies could help treat viral infections or enhance antitumor immune responses.
Recent studies also explore TLR3's role in vaccine adjuvants and its involvement in neuroinflammatory conditions. However, challenges remain in understanding tissue-specific TLR3 interactions and avoiding off-target effects. CD289 antibodies continue to aid in unraveling these complexities, offering insights into TLR3's dual role in protective immunity and pathological inflammation. Their applications bridge basic research and translational medicine, highlighting their importance in immunology and drug discovery.
×
